TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Intuitive Surgical Inc (ISRG)

Healthcare Medical Instruments & Supplies
353.30 $
+0.1% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Intuitive Surgical Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Trading Day

Previous Close
353.00$
Open
350.80$
Day High
355.10$
Day Low
348.90$
Volume
2,458,856shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
332.00 $ 592.90 $
07/23/2026 01/06/2026

Current price 353.30 $ — 8% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
125.1$B
Shares Outstanding
358Mio.
Float
98.0%
Beta
1.5

Performance

Perf. 1M
-4.20%
Perf. 3M
-10.30%
Perf. 6M
-29.70%
YTD Performance (%)
-28.80%
52-Week-High Distance
-33.8%
Perf. 1Y
-26.56%
Perf. 3Y
8.92%
Perf. 5Y
6.91%
Perf. 10Y
357.05%
Perf. Since Inception
17,505.76%

Technical Indicators

MA 38 Days
391.50$
MA 50 Days
399.40$
MA 200 Days
481.90$
RSI (14)
40.0
Volatility 30 Days
59.8%
Volatility 250 Days
36.0%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
43.5
Forward P/E
32.8
PEG
1.7
P/B
7.2
P/S
11.3
EV/EBITDA
28.2
Price/FCF
37.5

Profitability

Gross Margin
66.7%
EBIT Margin
30.9%
Net Margin
28.4%
Return on Equity
17.2%
Return on Assets
10.5%

Balance Sheet & Safety

Equity Ratio
86.9%
Debt/Equity
fortress balance sheet
Altman Z″
15.03
very solid
Piotroski
8 out of 9

Growth

Sales Growth Last Quarter
23.00%
EPS Growth Last Quarter
18.80%
Sales Growth (Year)
20.51%
Forward Sales Growth
13.23%
Forward EPS Growth
13.10%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
4
RS Rating
16
EPS Rating
65
very solid
Piotroski
8 out of 9
Fundamental Rating
B (72 out of 100)
fortress balance sheet
Altman Z″
15.03

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 353.30 $
Price Target (average) 477.25 $

The price target sits 35.1% above the current price.

Consensus
Sell
Analyst Ratings
33
Distribution of Recommendations
Strong Buy 14
Buy 8
Hold 10
Sell 0
Strong Sell 1

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 10.79 10.66 – 11.08 11,773 20.9% 26
12/31/2027 12.07 11.28 – 12.72 13,250 11.8% 27

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

20. Oct 2026 · after the close · Q3 2026
Expected Earnings per Share
2.63 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 2,413.5 $M Q4 2025: Q1 · 2,253.4 $M Q1 2025: Q2 · 2,440.0 $M Q2 2025: Q3 · 2,505.1 $M Q3 2025: Q4 · 2,866.2 $M Q4 2026: Q1 · 2,770.8 $M Q1 2026: Q2 · 2,892.3 $M Q2

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 1.88 11.30 2,414 25.20 28.40 823 511
2025: Q1 1.92 26.70 2,253 19.20 31.00 582 465
2025: Q2 1.81 23.90 2,440 21.40 27.00 715 560
2025: Q3 1.95 25.00 2,505 22.90 28.10 841 736
2025: Q4 2.21 17.00 2,866 18.80 27.70 893 730
2026: Q1 2.28 19.20 2,771 23.00 29.60 912 809
2026: Q2 2.29 26.50 2,892 18.50 28.30 1,061 1,061
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 2,704 945 736 2.08 1,043 5,778 6,487
2017 3,129 1,055 660 1.89 1,144 4,727 5,758
2018 3,724 1,199 1,128 3.16 1,170 6,679 7,847
2019 4,479 1,375 1,379 3.85 1,598 8,285 9,733
2020 4,358 1,050 1,061 2.94 1,485 9,759 11,169
2021 5,710 1,821 1,705 4.66 2,089 11,952 13,555
2022 6,222 1,577 1,322 3.65 1,491 11,042 12,974
2023 7,124 1,767 1,798 5.03 1,814 13,308 15,442
2024 8,352 2,349 2,323 6.42 2,415 16,434 18,839
2025 10,065 2,946 2,856 7.87 3,031 17,824 20,631

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Intuitive Surgical, Inc. entwickelt, fertigt und vermarktet Produkte, mit denen Ärzte und Gesundheitsdienstleister die Qualität und Zugänglichkeit minimalinvasiver Versorgung verbessern können – in den USA und international.

Employees17,021
HeadquartersSunnyvale, CA
Address1020 Kifer Road, 94086-5304 Sunnyvale, United States
Phone408 523 2100
Websiteintuitive.com
IPO Date13. Jun 2000
ISINUS46120E6023
Stock Split3:1 on 10/05/2021

Management

Management
Name Title Birth Year
Gary S. Guthart Ph.D. Executive Chair 1966
David J. Rosa CEO & Director 1968
Jamie E. Samath Executive VP, CFO & Enterprise Technology Leader 1971
Henry L. Charlton Senior VP of Global Business Operations 1970
Gary H. Loeb J.D. Executive VP and Chief Legal & Compliance Officer 1970
Fredrik Widman VP, Principal Accounting Officer & Corporate Controller
Milind Wagle Chief Information Officer
Daniel P. Connally C.F.A. VP & Head of Investor Relations
Christopher R. Carlson Ph.D. Executive Vice President of Research, Corporate Development, Corporate Strategy & Intuitive Ventures
Patricia L. Wadors Senior VP & Chief Human Resources Officer 1965

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
31. Jul 2026 Brosius Mark EVP & Chief Mfg and Supply Cha Sell 28 351.00 9,828
30. Jul 2026 Brosius Mark EVP & Chief Mfg and Supply Cha Sell 28 346.83 9,711
29. Jul 2026 Brosius Mark EVP & Chief Mfg and Supply Cha Sell 28 360.21 10,086
28. Jul 2026 Brosius Mark EVP & Chief Mfg and Supply Cha Sell 28 365.58 10,236
27. Jul 2026 Brosius Mark EVP & Chief Mfg and Supply Cha Sell 28 344.00 9,632
10. Jul 2026 Rosa David J. Chief Executive Officer (CEO) Other 947 411.55 389,738
10. Jul 2026 Rosa David J. Chief Executive Officer (CEO) Other 1,910 0.00

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?